A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

NCT06136559 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1200

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

DRUG: Nemtabrutinib
DRUG: Ibrutinib
DRUG: Acalabrutinib

Sponsor

Merck Sharp & Dohme LLC